Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ablynx, a Sanofi company
Subjects who completed the 24-week assessment period and achieved at least 20% improvement in swollen joint count (SJC) and/or tender joint count (TJC) at Week 24 of study ALX0061-C201 were invited to participate in an open-label extension (OLE) study ALX0061-C203 (NCT02518620), if the study was approved in their country and selection criteria were met.
Age
18–74
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of RA for at least 6 months prior to screening, and American College of Rheumatology (ACR) functional class I-III
Subjects treated with and tolerating MTX
Active RA
Others as defined in the protocol
You may not be if
Have been treated with disease-modifying antirheumatic drugs (DMARDs)/systemic immunosuppressives other than MTX.
Have received approved or investigational biological or targeted synthetic DMARD therapies for RA less than 6 months prior to screening.
Have a history of toxicity, non-tolerance, primary non-response or inadequate response to a biological therapy, or targeted synthetic DMARDs, for RA.
Have received prior therapy blocking the interleukin-6 (IL-6) pathway, at any time.
Others as defined in the protocol
Clareo Health | A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
